

ISSUE DATE	EDITORIAL FEATURE	ADDED VALUE AND BONUS DISTRIBUTION	SPACE CLOSING	MATERIALS DUE
JANUARY	<p><b>Ninth annual report: Top 10 pipelines and the most innovative pipeline</b> Depth, diversity, innovation, and commercial potential are hallmarks of the industry's best pipelines. This special report reveals which pipelines are the best, what's in them, and names the one that's the most innovative.</p>	<p><b>R&amp;D Directions Drug Development Summit,</b> "Cancer R&amp;D and Its Impact on Building a Winning Pipeline," Phoenix, AZ February 6-9, 2005</p>	Dec. 10, 2004	Dec. 17, 2004
FEBRUARY	<p><b>Clinical trials made public</b> Questions surrounding the mandatory public revealing of clinical trial results are answered in this special report.</p>		Jan. 14, 2005	Jan. 19, 2005
MARCH	<p><b>Fourth annual report: 100 great investigational drugs</b> Hundreds of drugs in Phase I through Phase III are reviewed, and those found to be truly unique are profiled.</p>	<p><b>Partnerships with CROs</b> Dallas, TX April 4-6, 2005</p>	Feb. 11, 2005	Feb. 15, 2005
APRIL	<p><b>Third annual report: Patient recruitment made easy</b> A report on the most critical determinants of patient enrollment success, with a focus on recruiting patients outside the United States, western Europe, and Japan.</p>		Mar. 11, 2005	Mar. 16, 2005
MAY	<p><b>First annual report: Partnerships in drug development</b> As pharmaceutical companies seek to license compounds for development, this report investigates what they are looking for and with what companies they are partnering.</p>	<p><b>DIA Annual Meeting</b> Washington, DC June 26-30, 2005</p>	Apr. 15, 2005	Apr. 22, 2005
JUNE	<p><b>Tenth annual special directory: From Pipeline to Market</b> An exclusive, special directory that compiles thousands of investigational drugs in Phases I through III clinical trials, drugs awaiting approval, and products recently approved. Plus, the Product to Watch is profiled and the head of R&amp;D from the company developing the drug is interviewed.</p>	<p><b>DIA Annual Meeting</b> Washington, DC June 26-30, 2005</p>	May 11, 2005	May 18, 2005
JULY/AUGUST	<p><b>Second annual report: The biotech pipeline-critical to big pharma's future</b> Increasingly, major pharmaceutical companies are in need of drugs in development by emerging biotech companies, and this report focuses on the development partnerships that result.</p>		Jun. 7, 2005	Jun. 14, 2005
SEPTEMBER	<p><b>Tenth annual report: Contract research organizations</b> Public contract research organizations are ranked by revenue and those that took part in significant events shaping them and the industry are profiled.</p>		Aug. 12, 2005	Aug. 19, 2005
OCTOBER	<p><b>Fifth annual report: Top 10 areas of research</b> The disease categories with the most significant amount of investigational activity are profiled, and extensive pipeline data is provided for each category.</p>		Sep. 9, 2005	Sep. 16, 2005
NOVEMBER/ DECEMBER	<p><b>Second annual report: Companion diagnostics</b> With the FDA's guidance on pharmacogenomic data submission, the industry is expected to accelerate its development of therapeutics and companion diagnostics toward the goal of personalized medicine. This report focuses on these companies and their products.</p>	<p><b>R&amp;D Directions Drug Development Summit</b> Phoenix, AZ February 2006</p>	Oct. 14, 2005	Oct. 21, 2005
DECEMBER SUPPLEMENT	<p><b>Guide to Contract Research Services</b> The Guide is a unique, fully-sponsored publication allowing all outsourcing companies to present their stories and qualifications to the industry through a self-written company profile.</p>	<p><b>R&amp;D Directions Drug Development Summit</b> Phoenix, AZ February 2006</p>	Nov. 11, 2005	Nov. 18, 2005

Plus all the regular news and departments our readers expect: **R&D Business, Contract Research, eR&D, Drugs in Development, Drugs Filed for Approval, and People on the Move**

*All features and special reports subject to change*